AVR 118
Alternative Names: AVR-118; AVR123; EOM-613; OHR-118; OHR/AVR-118; Peptide R; Product R; Reticulose; Substance RLatest Information Update: 09 Nov 2023
Price :
$50 *
At a glance
- Originator Advanced Viral Research
- Developer Advanced Viral Research; EOM Pharmaceuticals; McGill University; NeuBase Therapeutics; University of the West Indies School of Clinical Medicine and Research
- Class Antineoplastics; Antirheumatics; Antivirals; Peptide nucleic acids
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II COVID 2019 infections
- Discontinued Anorexia; Cachexia; Cancer; Haematological malignancies; HIV infections; Human papillomavirus infections; Multiple sclerosis; Rheumatoid arthritis; Type 2 diabetes mellitus; Wounds